COVAIL
Cross-source consensus on COVAIL from 1 sources and 5 claims.
1 sources · 5 claims
Benefits
Risks & contraindications
Evidence quality
Where it comes from
Highlighted claims
- The COVAIL case study used Stages 2 and 4. — Efficient estimation of cumulative incidence curves via data fusion with surrogates: application to integrated analysis of vaccine trial and immunobridging data
- Stage 2 included 154 per-protocol participants assigned to Omicron-containing vaccines and 47 assigned to monovalent Prototype vaccine. — Efficient estimation of cumulative incidence curves via data fusion with surrogates: application to integrated analysis of vaccine trial and immunobridging data
- Using Stage-2 and Stage-4 data, estimated Stage-4 BA.4/5 + Prototype cumulative incidence was 4.8% at Day 91 and 6.8% at Day 188. — Efficient estimation of cumulative incidence curves via data fusion with surrogates: application to integrated analysis of vaccine trial and immunobridging data
- A COVAIL diagnostic analysis found evidence against the no controlled direct effects assumption. — Efficient estimation of cumulative incidence curves via data fusion with surrogates: application to integrated analysis of vaccine trial and immunobridging data
- The COVAIL diagnostic suggested that Day 15 BA.4/BA.5 neutralizing antibody titer did not capture all relevant pathways. — Efficient estimation of cumulative incidence curves via data fusion with surrogates: application to integrated analysis of vaccine trial and immunobridging data